A Retrospective Cost-effectiveness Analysis of Interferon as Adjuvant Therapy in High-risk Resected Cutaneous Melanoma

By Messori A.   Becagli P.   Trippoli S.   Tendi E.  

European Journal of Cancer, Vol. 33, Iss. 9, 1997-08 ,pp. : 1373-1379

Elsevier

Access to resources Recommend Favorite

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

By Norum J.   Olsen J. A.   Wist E. A.   Lønning P. E.  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

By Brandberg Yvonne   Johansson Hemming   Aamdal Steinar   Bastholt Lars   Hernberg Michaela   Stierner Ulrika   von der Maase Hans   Hansson Johan    

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1086-1093

Informa Healthcare

Access to resources Recommend Favorite

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma: A single institution's experience

By Tas Faruk   Kurul Sidika   Camlica Hakan   Topuz Erkan  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 471-477

Humana Press, Inc

Access to resources Recommend Favorite

Identification of a High-Risk Subgroup of Patients with Resected pT3 Oral Cavity Cancer in Need of Postoperative Adjuvant Therapy

By Liao Chun-Ta  

Annals of Surgical Oncology, Vol. 18, Iss. 9, 2011-09 ,pp. : 2569-2578

Springer Publishing Company

Access to resources Recommend Favorite